Washington: An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a phase 1 clinical trial, say scientists.
The candidate vaccine contains segments of Ebola virus genetic material from two virus species, Sudan and Zaire.
The Ebola virus genetic material is delivered by a carrier virus (chimpanzee-derived adenovirus 3 or cAd 3) that causes a common cold in chimpanzees but causes no illness in humans.
The candidate NIAID/GSK Ebola vaccine was developed collaboratively by scientists at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and GlaxoSmithKline (GSK).
"The unprecedented scale of the current Ebola outbreak in West Africa has intensified efforts to develop safe and effective vaccines, which may play a role in bringing this epidemic to an end and undoubtedly will be critically important in preventing future large outbreaks," said NIAID Director Anthony S Fauci.
"Based on these positive results from the first human trial of this candidate vaccine, we are continuing our accelerated plan for larger trials to determine if the vaccine is efficacious in preventing Ebola infection," Fauci said.
The trial at the NIH Clinical Center in Bethesda, Maryland enrolled volunteers between the ages of 18 and 50.
Ten volunteers received an intramuscular injection of vaccine at a lower dose and 10 received the same vaccine at a higher dose.
At two weeks and four weeks following vaccination, the researchers tested the volunteers' blood to determine if anti-Ebola antibodies were generated.
All 20 volunteers developed such antibodies within four weeks of receiving the vaccine. Antibody levels were higher in those who received the higher dose vaccine.
The investigators also analysed the research participants' blood to learn whether the vaccine prompted production of immune system cells called T cells.
A recent study by VRC scientist Nancy J Sullivan and colleagues showed that non-human primates inoculated with the candidate NIAID/GSK vaccine developed both antibody and T-cell responses, and that these were sufficient to protect vaccinated animals from disease when they were later exposed to high levels of Ebola virus.
The experimental NIAID/GSK vaccine did induce a T-cell response in many of the volunteers, including production of CD8 T cells, which may be an important part of immune protection against Ebola viruses.
Four weeks after vaccination, CD8 T cells were detected in two volunteers who had received the lower dose vaccine and in seven of those who had received the higher dose.
The study is published in the New England Journal of Medicine.
Comments
0 comment